Liraglutide for adults living with obesity

利拉鲁肽 肥胖 协议(科学) 老年学 医学 梅德林 物理疗法 临床试验 荟萃分析 儿科 内科学 糖尿病
作者
Nicolás Meza,Javier Bracchiglione,Camila Micaela Escobar Liquitay,Eva Madrid,Lucia B Varela,Yang Guo,Gerard Urrútia,S. F. Schaf er,S. Tiller,Kamyar Shokraee,Felipe Alvarez Busco,Iván Solà,Miranda Ocara Vargas,Victoria Novik A,Daniel Poloni,Juan Víctor Ariel Franco
出处
期刊:The Cochrane library [Wiley]
卷期号:2025 (11): CD016017-CD016017 被引量:2
标识
DOI:10.1002/14651858.cd016017
摘要

RATIONALE: Obesity is a complex chronic condition linked to various comorbidities, such as hypertension, diabetes, and dyslipidaemia, with a significant global burden. Standard treatments, such as diet modifications and physical activity, often have limited effects and poor compliance. Pharmacological options, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), show promise for individuals with obesity. This is one of three reviews investigating GLP-1RAs for adults living with obesity. OBJECTIVES: To assess the effects of liraglutide, a GLP-1RA, for adults living with obesity. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, LILACS, and two trials registries on 17 December 2024. ELIGIBILITY CRITERIA: We included randomised controlled trials (RCTs) that compared liraglutide at any dose with placebo or no treatment, structured lifestyle-modification programmes, other anti-obesity medications, or other GLP-1RAs, in adults with obesity, with a minimum follow-up of six months. OUTCOMES: Critical outcomes were body weight, adverse events, major adverse cardiovascular events (MACE), quality of life, and mortality. Important outcomes were waist circumference, heart failure, diabetes-related outcomes, blood pressure-related outcomes, liver disease-related outcomes, obstructive sleep apnoea, and lipid metabolism-related outcomes. We prioritised critical outcomes for the main comparison of interest, liraglutide versus placebo, for the Abstract and key summary of findings tables. RISK OF BIAS: We used the original Cochrane tool for assessing risk of bias (RoB 1). SYNTHESIS METHODS: We synthesised results for each outcome using meta-analysis, where possible, with a random-effects model. We assessed the certainty of evidence for each outcome using GRADE. INCLUDED STUDIES: We included 24 RCTs involving 9937 participants, aged 31.3 to 64.7 years, primarily from middle- and high-income countries. Most studies compared liraglutide to placebo, alone or within multi-arm designs (two studies included semaglutide as an active comparator, one included orlistat); two studies compared liraglutide versus structured lifestyle-modification programmes. Studies included participants with weight-related comorbidities; 17 focused on specific subgroups, including people with diabetes, non-alcoholic fatty liver disease, polycystic ovary syndrome, and obstructive sleep apnoea. All studies had medium-term follow-ups, and three also provided data at long-term follow-up. Twenty-two studies were funded by the drug manufacturer, with major involvement in design, conduct, analysis, or reporting in 13 studies. SYNTHESIS OF RESULTS: = 78%; 18 studies, 6651 participants; moderate-certainty evidence). Liraglutide may increase any adverse events (RR 1.07, 95% CI 1.04 to 1.11; I² = 28%; 16 studies, 8147 participants; low-certainty evidence) and serious adverse events (RR 1.20, 95% CI 1.00 to 1.43; I² = 0%; 20 studies, 8487 participants; low-certainty evidence). The evidence is very uncertain about the effects of liraglutide on non-serious adverse events (RR 1.14, 95% CI 1.05 to 1.24; I² = 76%; 17 studies, 7440 participants; very low-certainty evidence) and on adverse events leading to withdrawal (RR 1.98, 95% CI 1.30 to 3.02; I² = 47%; 19 studies, 8628 participants; very low-certainty evidence). Liraglutide likely results in little to no clinically meaningful difference in MACE (RR 0.86, 95% CI 0.66 to 1.10; I² = 0%; 6 studies, 5762 participants; moderate-certainty evidence). Liraglutide likely results in little to no difference in quality of life measured by the IWQOL-Lite-CT physical function (MD 2.90, 95% CI -0.08 to 5.89; I² = 58%; 6 studies, 3733 participants; moderate-certainty evidence). The evidence is very uncertain about the effect of liraglutide on mortality (RR 0.44, 95% CI 0.08 to 2.25; I² = 0%; 18 studies, 8224 participants; very low-certainty evidence). Liraglutide versus placebo (long-term: 104 to 162 weeks) Liraglutide may result in little to no clinically meaningful difference in percentage weight change from baseline (MD -4.34, 95% CI -5.26 to -3.43; I² = 0%; 2 studies, 1262 participants; low-certainty evidence), and likely increases the number of participants achieving 5% weight reduction (RR 1.78, 95% CI 1.51 to 2.09; I² = 0%; 2 studies, 1262 participants; moderate-certainty evidence). The evidence is very uncertain about the effect of liraglutide on any adverse events (RR 1.19, 95% CI 0.93 to 1.52; I² = 93%; 2 studies, 2640 participants; very low-certainty evidence) and on non-serious adverse events (RR 1.19, 95% CI 0.94 to 1.51; I² = 93%; 2 studies, 2640 participants; very low-certainty evidence). Liraglutide may increase serious adverse events (RR 1.20, 95% CI 0.98 to 1.48; I² = 0%; 2 studies, 2640 participants; low-certainty evidence) and adverse events leading to withdrawal (RR 2.16, 95% CI 1.59 to 2.93; I² = 0%; 2 studies, 2640 participants; low-certainty evidence). The evidence is very uncertain about the effect of liraglutide on MACE (RR 0.83, 95% CI 0.20 to 3.46; I² not applicable; 1 study, 2248 participants; very low-certainty evidence). Liraglutide likely results in little to no clinically meaningful difference in quality of life measured by the IWQoL-Lite-CT physical function (MD 3.81, 95% CI 1.03 to 6.59; I² not applicable; 1 study, 863 participants; moderate-certainty evidence). The evidence is very uncertain about the effect of liraglutide on mortality (RR 0.81, 95% CI 0.16 to 4.17; I² = 0%; 2 studies, 2640 participants; very low-certainty evidence). AUTHORS' CONCLUSIONS: Liraglutide likely increases the proportion of people achieving at least 5% weight loss at medium-term follow-up; this effect is likely to be sustained at longer-term follow-up. Medium- or long-term impact on percentage weight change, MACE, quality of life, and mortality may be limited or uncertain. Liraglutide may lead to an increase in adverse events, including serious adverse events in both the medium and long term, which might further limit the sustainability of the initial effects. The drug manufacturer funded 22 studies, raising concerns about potential conflicts of interest. Further independent and long-term studies are needed to better understand the broader effects of liraglutide in the management of obesity. FUNDING: World Health Organization (WHO) REGISTRATION: Original protocol (2022): DOI 10.1002/14651858.CD015092 Updated protocol (2025): PROSPERO CRD420250654193.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
思源的应助被清脆绮山采纳,获得10
1秒前
小猪发布了新的文献求助30
1秒前
Gentleman完成签到,获得积分10
1秒前
NexusExplorer的应助被激动的绿竹采纳,获得10
2秒前
xushanqi发布了新的文献求助10
2秒前
kuku的应助被xzl123采纳,获得10
3秒前
我是老大的应助被楚子航采纳,获得10
3秒前
磊大彪完成签到 ,获得积分10
4秒前
4秒前
5秒前
liu完成签到,获得积分10
5秒前
5秒前
6秒前
6秒前
辛勤的纸飞机完成签到 ,获得积分10
6秒前
在水一方的应助被OoO采纳,获得10
6秒前
FashionBoy的应助被积极的黑猫采纳,获得10
7秒前
Orange的应助被zgx采纳,获得10
7秒前
tjz发布了新的文献求助10
8秒前
9秒前
9秒前
hua发布了新的文献求助10
9秒前
ding的应助被傲娇的笙采纳,获得10
9秒前
NexusExplorer的应助被篝火采纳,获得10
10秒前
10秒前
水本无忧87完成签到,获得积分10
10秒前
xuyuanyuan发布了新的文献求助10
10秒前
1111chen完成签到,获得积分10
11秒前
tinaping发布了新的文献求助10
11秒前
sweet发布了新的文献求助10
11秒前
彭于晏的应助被形随将至采纳,获得10
11秒前
11秒前
11秒前
12秒前
13秒前
深情安青的应助被霁月采纳,获得10
13秒前
NANO完成签到,获得积分10
13秒前
学阿斗发布了新的文献求助10
13秒前
甜园将芜完成签到,获得积分10
13秒前
ding的应助被江江采纳,获得20
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181014
求助须知:如何正确求助?哪些是违规求助? 9571039
关于积分的说明 21816042
捐赠科研通 7777369
什么是DOI,文献DOI怎么找? 3433378
关于科研通互助平台的介绍 2557621
邀请新用户注册赠送积分活动 2479385